Global Antibodies in Oncology Market: Overview

Monoclonal antibodies are very highly specific to cancer cells because they are capable of binding with the proteins on their surface and then trigger an immediate immune response. Cancer has been one of the leading reasons for death across the globe and for a while. According to the World Health Organization (WHO), nearly 70% of all the cancer-related deaths happen in middle and low-income countries. The increase in data is likely to provide the foundation for any national policy on cancer, thereby resulting in an increase in the percentage of people opting for treatment of cancer. In the healthcare segment, cancer has been one issue of immense concerns. As such, the increased utilization of monoclonal antibodies for the purpose of treatment of cancer is fuelling the growth of the global antibodies in oncology market.

The global antibodies in oncology market is likely to influenced by factors such as augmented investment in research and development activities of genome studies, increased prevalence of cancer, and rapid progress made in the specificity of monoclonal antibodies to target cancer cells.

The report on the global antibodies in oncology market offers a detailed view of the changes and developments that have taken place the cancer treatment. These changes are likely to shape future course of the global antibodies in oncology market over the timeframe of projection. These insights are expected to help the market players and investors to assess the completive ecosystem and formulate strategies.

Global Antibodies in Oncology Market: Trends and Opportunities

Increased Research and Development on Monoclonal Antibodies to Boost Market

The use of monoclonal antibodies for the treatment of cancer has increased substantially. The increasing availability of these agents has allowed pharmaceutical companies to come up with innovative combination approaches that provide even better and greater insight into the immune system of the human body to develop monoclonal antibodies that are more efficacious. As the prevalence of cancer rises, the global antibodies in oncology market are poised for considerable growth over the tenure of projection.

The monoclonal antibodies have already been playing an important role in the treatment of several types of cancer, however, utilization of these antibodies in other facets of cancer treatment remain untapped. Nevertheless, research and development activities for this purpose have been undertaken to know and understand about the reason for difference between normal cells and cancer cells and use of monoclonal antibodies to make use if these differences. This factor is likely to offer copious growth opportunities for the global antibodies in oncology market in the years to come.

Several pharmaceutical companies are also trying to find means and ways to make these drugs more effective and safer. It is expected that newly developed monoclonal antibodies will offer solution to a wide range of problems and might not cause immune reactions.

On the other hand, regulatory guidelines for cancer-related monoclonal antibodies are an extremely rigorous process in most parts of the world. Stringent regulations are estimated to restrict the growth of the global antibodies in oncology market in the years to come.

Global Antibodies in Oncology Market : Regional Outlook

Key regions in the global antibodies in oncology market comprise the regional market of North America, the Middle East and Africa (MEA), Europe, Asia Pacific, and Latin America. North America is estimated to dominate the global cancer monoclonal antibodies market owing to the presence of already established advanced healthcare infrastructures, augmented spending by the governments for management and control of infection. In addition, high prevalence of cancer in the region is likely to help the global antibodies in oncology market to prosper in the years to come.

Global Antibodies in Oncology Market : Companies Mentioned in Report

Prominent players profiled in the report on global antibodies in oncology market include Elan Human Genome Sciences Inc., Novartis International AG, GlaxoSmithKline plc, Biogen Idec Inc., Bristol Myers Squibb Co., and AstraZeneca plc.

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Antibodies Oncology Market

Pre Book